Carmichael Hill & Associates, Inc. Cassava Sciences Inc Transaction History
Carmichael Hill & Associates, Inc.
- $279 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
189Shares Held
16MCall Options Held
3.7MPut Options Held
8.77M-
Black Rock Inc. New York, NY3.22MShares$7.79 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.51MShares$6.08 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.44 Million0.0% of portfolio
-
State Street Corp Boston, MA997KShares$2.41 Million0.0% of portfolio
-
Ubs Group Ag931KShares$2.25 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $97M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...